Edition 1, 2021
Viral Respiratory Molecular Program
NRL conducted a Pilot SARS-CoV-2 Molecular Qualitative Program in 2020 using inactivated SARS-CoV-2 clinical virus. Thanks for all the participating laboratories. Recently, NRL released the final report of this pilot program.
Based on the experience of SARS-CoV-2 pilot program, NRL further developed “Viral Respiratory Molecular” programs incorporated with Influenza A, Flu B and RSA. The Viral Respiratory Molecular (RESP435) is applicable for both laboratories and Point-Of-Care sites performing molecular testing for Influenza A and B, RSV and SARS-CoV-2. This program is a respiratory scheme that consists of clinical samples that are real, inactivated virus that enables the monitoring of extraction efficiency as well as detection of analyte. For easier logistic and storage, RESP panels are validated to be shipped and stored at ambient temperature. this EQA scheme is ideal for both sophisticated laboratories using multiplex molecular assays as well as Point-Of-Care facilities using platforms such as the Cepheid GeneXpert.